Bradley Estes, PhD, Cytex President and COO, presented the latest results from studies the company has been conducting in cooperation with researchers at North Carolina State University School of Veterinary Medicine. In these studies, Cytex and NC State investigators demonstrated the ability of Cytex patented implants to repair cartilage damage in a model of osteoarthritis. […]
Cytex shareholders voted unanimously to approve the following changes to company management: Farshid Guilak, PhD, was elected Executive Chairman of the Board; Bradley Estes, PhD, was promoted to President and Chief Operating Officer and was elected to the Cytex Board of Directors, and; David Pritchard, Cytex CEO, was elected to the Cytex Board of Directors. […]
Cytex is pleased to announce that David Pritchard has joined the company, effective immediately, as Chief Executive Officer. Mr. Pritchard is an experienced biotechnology executive who has previously served as CEO of several startups and early stage companies. He has worked in the biotech industry in Boston, San Diego, San Francisco, Philadelphia, the Pacific Northwest […]
Cytex is excited to begin a grant-funded project entitled “Evaluating the Safety and Efficacy of Cartilage Regeneration with Tunable Inflammation Resistance” studying the safety and efficacy of some of its next-generation regenerative medicine techniques in a small animal model.
Cytex today received a communication from the US Patent and Trademark Office that its’ application, Articular Cartilage Repair, has been allowed. Cytex had previously been awarded US patents for claims covering Tissue Engineering Methods and Compositions.
Cytex is pleased to announce the receipt of four new research awards from the National Institutes of Health. Two awards are part of the recent Commercialization Readiness Pilot initiative offered by NIH, and will assist Cytex in its commercialization efforts of its hip implant. The other two awards are part of NIH’s SBIR (Small Business […]
Dr. Estes was invited to speak at the Orthopaedic Manufacturing & Technology Exposition and Conference Tech Center on June 14, 2017. Dr. Estes presented a review of functional tissue engineering methods and novel approaches to regenerate and repair diseased cartilage along with an overview of advancements in stem cell research.
Dr. Vince Willard recently co-authored two papers studying applications of gene editing of stem cells to prevent inflammation. One paper, entitled “CRISPR/Cas9 Editing of Murine Induced Pluripotent Stem Cells for Engineering Inflammation-Resistant Tissues,” published in the May 2017 edition of Arthritis & Rheumatology. The other paper, “Genome Engineering of Stem Cells for Autonomously Regulated, Closed-Loop […]
Cytex’s intellectual portfolio is further strengthened with the most recent US patent continuation, “Tissue Engineering Methods and Composition,” Patent No.: US 9,649,409 B2 on May 16, 2017.
Cytex is excited to receive a Phase 2 STTR award from NIH to fund a project “Unicondylar Resurfacing in Ovine Osteoarthritis”. This study examines the efficacy of Cytex’s cartilage resurfacing implant in an ovine knee model.